Figure 4: Overall survival (OS) and progression-free survival (PFS) based on absolute lymphocyte count at day 15 (ALC-15) and absolute monocyte count at day 15 (AMC-15) categories post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Group 1 was patients with an ALC-15 = 500 cells/Ál and an AMC < 600 cells/Ál; group 2 was patients with an ALC-15 < 500 cells/Ál and an AMC < 600 cells/Ál; group 3 was patients with an ALC-15 = 500 cells/Ál and an AMC = 600 cells/Ál; and group 4 was patients with an ALC-15 < 500 cells/Ál and an AMC = 600 cells/Ál. OS (4a) was better in group 1 compared with the other groups: group 1 vs 2, p< 0.0001; group 1 vs 3, p < 0.0001; group 1 vs 4, p < 0.0001; group 2 vs 4, p < 0.0001; and group 3 vs 4, p < 0.0001. However, no difference in OS was observed between groups 2 and 3, p = 0.9. PFS (4b) was better in group 1 compared with the other groups: group 1 vs 2, p< 0.0001; group 1 vs 3, p < 0.0001; group 1 vs 4, p < 0.0001; group 2 vs 4, p < 0.0001; and group 3 vs 4, p < 0.0001. However, no difference in PFS was observed between groups 2 and 3, p = 0.8.